To improve melanoma outcomes, the focus on prevention, early detection and new treatment strategies must continue
Over the past 5 years, we have seen a dramatic response to the intense biological research into late-stage, metastatic melanoma, with therapies targeting melanoma metastases and improving an individual’s immune response to the disease. This has led to an improvement in progression-free and overall survival in a group of patients who would have previously been treated with drugs that had little effect. Intense research and clinical trials continue with the aim of identifying patients most likely to respond, as well as exploring new combinations of therapies with this new paradigm for melanoma treatment.
- 1. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 2016; 136: 1161-1171.
- 2. Green AC, Baade P, Coory M, et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012; 30: 1462-1467.
- 3. Davis NC. Cutaneous melanoma: the Queensland experience. Curr Probl Surg 1976; 13: 1-63.
- 4. Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev 2015; 24: 141-149.
- 5. Ainger SA, Jagirdar K, Lee KJ, et al. Skin pigmentation genetics for the clinic. Dermatology 2017; 233: 1-15.
- 6. Janda M, Soyer HP. Greater precision in melanoma prevention. JAMA Dermatol 2017; 153: 18-19.
- 7. Janda M, Soyer HP. Automated diagnosis of melanoma. Med J Aust 2017; 207: 361-362.
- 8. Mar VJ, Chamberlain AJ, Kelly JW, et al. Clinical practice guidelines for the diagnosis and management of melanoma: melanomas that lack classical clinical features. Med J Aust 2017; 207: 348-350.
- 9. Pan Y, Adler NR, Wolfe R, et al. Nodular melanoma is less likely than superficial spreading melanoma to be histologically associated with a naevus. Med J Aust 2017; 207: 333-338.
- 10. Australian Institute of Health and Welfare. Skin cancer in Australia (AIHW Cat. No. CAN 96) Canberra: AIHW 2016.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.